Tolerability of Oral Paclitaxel in Cancer-Bearing Dogs
ClosedResearch Type
Ethos Discovery De Novo Study
Description
Paclitaxel is a human chemotherapeutic that has demonstrated a broad spectrum of activity against several human and canine cancers. Previous formulations of paclitaxel have been poorly absorbed in dogs, limiting its therapeutic value. Oraxol is a novel oral formulation of paclitaxel that is combined with a second drug, Encequidar, which improves this issue of poor absorption. Preclinical studies have demonstrated safety in dogs, making Oraxol an intriguing choice for further study in cancer-bearing dogs. The data collected from this study will help to inform future studies in the treatment of canine hemangiosarcoma, a common and aggressive cancer in dogs.
Eligibility criteria
- Dogs diagnosed with cancer of any kind
- Dogs weighing between 10kg (22lb) and 45kg (99lb)
- Dogs who have not received chemotherapy within 14 days of study entry
- Dogs with no significant kidney disease
- Dogs with no significant liver disease
Participating hospitals
- Massachusetts Veterinary Referral Hospital, Woburn, MA
- Peak Veterinary Referral Center, Williston, VT
- Pet Emergency & Specialty Center of Marin (PESCM), San Rafael, California
- VERC, Honolulu, HI
- Veterinary Specialty Hospital, Sorrento Valley, San Diego, CA
- Veterinary Specialty Hospital, North County, San Marcos, CA
- Wheat Ridge Animal Hospital, Wheat Ridge, CO
- WVRC – Waukesha, Waukesha, WI